0
USD
U.S. (TOLL FREE)
+1 (425) 388-2538
Automative

0
U.S. (TOLL FREE)
+1 (425) 388-2538

Secondary Progressive Multiple Sclerosis (SPMS) - Epidemiology Forecast to 2028

Published Date: April 2019
|
Report Code: DELV-Epid-233
Home | Category |Health |Health Conditions |Infectious Diseases
Secondary Progressive Multiple Sclerosis Epidemiology Forecast to 2028

Secondary Progressive Multiple Sclerosis (SPMS) - Epidemiology Forecast to 2028

Code: DELV-Epid-233
Report
April 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Secondary Progressive Multiple Sclerosis (SPMS) - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Secondary Progressive Multiple Sclerosis (SPMS) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Secondary Progressive Multiple Sclerosis (SPMS) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Secondary Progressive Multiple Sclerosis (SPMS) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Secondary Progressive Multiple Sclerosis (SPMS) outlook. It also includes the explanation of changing trends of epidemiology outlining the Secondary Progressive Multiple Sclerosis (SPMS) scenario.

Secondary Progressive Multiple Sclerosis (SPMS) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Secondary Progressive Multiple Sclerosis (SPMS) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Secondary Progressive Multiple Sclerosis (SPMS) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Secondary Progressive Multiple Sclerosis (SPMS) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Secondary Progressive Multiple Sclerosis (SPMS)

Key assessments
• Patient Segmentation in Secondary Progressive Multiple Sclerosis (SPMS)
• Secondary Progressive Multiple Sclerosis (SPMS) Risk & Burden
• Factors driving growth in a specific Secondary Progressive Multiple Sclerosis (SPMS) patient population

1. Report Introduction
2. Secondary Progressive Multiple Sclerosis (SPMS) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Secondary Progressive Multiple Sclerosis (SPMS) in 2016
2.2. Patient Share Distribution of Secondary Progressive Multiple Sclerosis (SPMS) in 2028
3. Disease Background and Overview: Secondary Progressive Multiple Sclerosis (SPMS)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Secondary Progressive Multiple Sclerosis (SPMS) in 7MM – By Countries
5. Epidemiology of Secondary Progressive Multiple Sclerosis (SPMS) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.1.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.1.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.1.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.4.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.4.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.4.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.5.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.5.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.5.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.6.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.6.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.6.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.7.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.7.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.7.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.8.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.8.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.8.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.9.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.9.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.9.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
6. Unmet Needs of the Secondary Progressive Multiple Sclerosis (SPMS)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) *
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)


List of Figures :

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

DelveInsight's "Secondary Progressive Multiple Sclerosis (SPMS) - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Secondary Progressive Multiple Sclerosis (SPMS) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Secondary Progressive Multiple Sclerosis (SPMS) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Secondary Progressive Multiple Sclerosis (SPMS) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Secondary Progressive Multiple Sclerosis (SPMS) outlook. It also includes the explanation of changing trends of epidemiology outlining the Secondary Progressive Multiple Sclerosis (SPMS) scenario.

Secondary Progressive Multiple Sclerosis (SPMS) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Secondary Progressive Multiple Sclerosis (SPMS) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Secondary Progressive Multiple Sclerosis (SPMS) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Secondary Progressive Multiple Sclerosis (SPMS) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Secondary Progressive Multiple Sclerosis (SPMS)

Key assessments
• Patient Segmentation in Secondary Progressive Multiple Sclerosis (SPMS)
• Secondary Progressive Multiple Sclerosis (SPMS) Risk & Burden
• Factors driving growth in a specific Secondary Progressive Multiple Sclerosis (SPMS) patient population

Read More

1. Report Introduction
2. Secondary Progressive Multiple Sclerosis (SPMS) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Secondary Progressive Multiple Sclerosis (SPMS) in 2016
2.2. Patient Share Distribution of Secondary Progressive Multiple Sclerosis (SPMS) in 2028
3. Disease Background and Overview: Secondary Progressive Multiple Sclerosis (SPMS)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Secondary Progressive Multiple Sclerosis (SPMS) in 7MM – By Countries
5. Epidemiology of Secondary Progressive Multiple Sclerosis (SPMS) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.1.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.1.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.1.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.4.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.4.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.4.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.5.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.5.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.5.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.6.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.6.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.6.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.7.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.7.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.7.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.8.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.8.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.8.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.9.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.9.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.9.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
6. Unmet Needs of the Secondary Progressive Multiple Sclerosis (SPMS)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

Read More

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) *
Table 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)


List of Figures :

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)

Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Site License

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Enterprise License

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)

RELATED REPORTS

Pneumonia Vaccine Market by Vaccine Type Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine by Product Type Prevnar 13 Synflorix and Pneumovax 23 and By Sector Public and Private by Distribution Channel Distribution Partner Companies Non governmental Organizations and Government Authorities Opportunity Analysis and Industry Forecast 2018 2025
Pneumonia Vaccine Market by Vaccine Type Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine by Product Type Prevnar 13 Synflorix and Pneumovax 23 and By Sector Public and Private by Distribution Channel Distribution Partner Companies Non governmental Organizations and Government Authorities Opportunity Analysis and Industry Forecast 2018 2025

Pneumonia Vaccine Market by Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine), by Product Type (Prevnar 13, Synflorix, and Pneumovax 23) and By Sector (Public and Private), by Distribution Channel (Distribution Partner Companies, Non-governmental Organizations and Government Authorities): Opportunity Analysis and Industry Forecast, 2018–2025

120 Pages
Type: Report
Code: ALLI-Auto-4T352
Wed Nov 20 00:00:00 UTC 2019

Add to Cart

Animal Vaccines Market by Product Type Attenuated Vaccines Inactivated Vaccines Subunit Vaccines Toxoid Vaccines Conjugate Vaccines Recombinant Vaccines and DNA Vaccines and Animal Type Companion animals Cattle Fish Pigs Poultry and Sheep Global Opportunity Analysis and Industry Forecast 2018 2025
Animal Vaccines Market by Product Type Attenuated Vaccines Inactivated Vaccines Subunit Vaccines Toxoid Vaccines Conjugate Vaccines Recombinant Vaccines and DNA Vaccines and Animal Type Companion animals Cattle Fish Pigs Poultry and Sheep Global Opportunity Analysis and Industry Forecast 2018 2025

Animal Vaccines Market by Product Type (Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, Recombinant Vaccines, and DNA Vaccines) and Animal Type (Companion animals, Cattle, Fish, Pigs, Poultry, and Sheep]: Global Opportunity Analysis and Industry Forecast, 2018 - 2025

120 Pages
Type: Report
Code: ALLI-Auto-0Z334
Wed Nov 20 00:00:00 UTC 2019

Add to Cart

Cholera Vaccine Market by Product Dukoral Shanchol Vaxchora Euvichol Euvichol Plus and others and End User Hospitals Clinics Research Academic Laboratories and Others Global Opportunity Analysis and Industry Forecast 2018 2025
Cholera Vaccine Market by Product Dukoral Shanchol Vaxchora Euvichol Euvichol Plus and others and End User Hospitals Clinics Research Academic Laboratories and Others Global Opportunity Analysis and Industry Forecast 2018 2025

Cholera Vaccine Market by Product (Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others) and End User (Hospitals & Clinics, Research & Academic Laboratories, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

120 Pages
Type: Report
Code: ALLI-Auto-3L367
Wed Nov 20 00:00:00 UTC 2019

Add to Cart

BCG Vaccines Sales Market by Drug Type Immune BCG and Therapy BCG Usage Tuberculosis and Bladder Cancer and End User Pediatrics and Adults Opportunity Analysis and Industry Forecast 2018 2025
BCG Vaccines Sales Market by Drug Type Immune BCG and Therapy BCG Usage Tuberculosis and Bladder Cancer and End User Pediatrics and Adults Opportunity Analysis and Industry Forecast 2018 2025

BCG Vaccines Sales Market by Drug Type (Immune BCG and Therapy BCG), Usage (Tuberculosis and Bladder Cancer), and End User (Pediatrics and Adults): Opportunity Analysis and Industry Forecast, 2018 - 2025

120 Pages
Type: Report
Code: ALLI-Auto-2B347
Wed Nov 20 00:00:00 UTC 2019

Add to Cart

0 Items
X
No items in the cart.
$0.0